Animal Testing in Pharmaceutical Development

Pharmaceutical testing requires animal testing at multiple stages of development, but the Three Rs framework and advancing alternative technologies are progressively reducing the welfare burden.

Key Facts

Approximately 3.4 million animal procedures were conducted in the UK in 2022, predominantly mice and fish
Drug safety testing accounts for approximately 20% of all animal use in UK research
Organoid technology, organ-on-chip and in silico models now replace animal tests in some discovery and early safety stages
The FDA Modernization Act 2.0 (2022) removed the legal requirement for animal testing for drug approval in the US
Most drugs that pass animal testing still fail in human clinical trials, indicating significant limitations of animal models

Welfare Considerations

Pharmaceutical animal testing creates a genuine ethical tension between the welfare of test animals and the potential health benefits for humans and other animals of the drugs being developed. The moral weight of this trade-off requires that the animal welfare burden be minimized through rigorous Three Rs application, and that alternatives be adopted whenever scientifically validated. The failure rate of animal-tested drugs in human trials suggests that the predictive value of animal models is lower than often assumed, providing both a welfare and a scientific argument for accelerating alternative development. The US regulatory reform removing mandatory animal testing is a significant policy shift enabling faster adoption of alternatives.

What You Can Do

Support NC3Rs and similar organizations funding validation of pharmaceutical alternatives to animal testing
Advocate for regulatory acceptance of validated non-animal testing methods by medicines agencies
Choose pharmaceutical companies with publicly committed Three Rs programs and alternative method adoption
Support open-access publication of alternative validation studies to accelerate their regulatory acceptance